ID
34696
Beskrivning
Study ID: 101998 Clinical Study ID: 101998 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor GlaxoSmithKline Collaborators N/A Phase Phase 3 Study Recruitment Status Completed Generic Name sumatriptan Trade Name Imitrex ,Imiject ,Imigran Study Indication Migraine Disorders The purpose of this form is to document the subjects intake of the investigational product and the status of treatment blind. It should be filled out at the final visit.
Nyckelord
Versioner (2)
- 2019-01-23 2019-01-23 -
- 2019-01-25 2019-01-25 - Sarah Riepenhausen
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
23 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Efficacy and Tolerability of TREXIMA Tablets vs. Placebo During Mild Migraine Study ID 101998
Investigational Product Use/Status of Treatment Blind
- StudyEvent: ODM
Similar models
Investigational Product Use/Status of Treatment Blind
- StudyEvent: ODM
C2347038 (UMLS CUI-2)
C2347038 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,2])